1. Scrip
  2. >>Focus On Asia

Allorion Rides Unconventional Discovery Platforms To Major Funding

But Partnerships Being Eyed

 
• By Dexter Jie Yan

Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.

unconventional approach
Allorion on track to develop unconventional approaches to undruggable targets • Source: Shutterstock

Allorion Therapeutics has become the latest Chinese biotech to rally sizable support from venture capital investors in its efforts to tackle oncology targets previously thought undruggable for small molecule modalities.

Allorion - which has bases and labs in both Natick, MA in the US and Guangzhou in China - announced on 10 March it had closed a series B round worth $50m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia